Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review Article
  • Published:

Role of one, two and three doses of high-dose chemotherapy with autologous transplantation in the treatment of high-risk or relapsed testicular cancer: a systematic review

Bone Marrow Transplantation volume 53, pages 1242–1254 (2018)Cite this article

Subjects

Abstract

Approximately 20–30% of patients with metastatic germ cell cancers (GCCs) can develop relapsed or refractory (RR) disease, about 40–50% of patients who relapse after salvage chemotherapy may reach long-term remission. The goal of this review was to identify patients who appear to benefit from high-dose chemotherapy (HDCT) and autologous stem cell transplant (ASCT). To access this, we performed a systematic medical literature review to evaluate the effectiveness of HDCT in the frontline setting, as well as in patients with RR testicular cancer. We searched databases for interventional clinical studies and identified 5883 studies. We selected 49 studies for inclusion, which included a total of 5985 patients. Seventeen studies reported results of newly diagnosed poor-risk GCC patients and 32 studies reported results of RR patients. For newly diagnosed patients with poor prognostic predictors, a risk adjusted strategy using unfavorable tumor marker decline with initial standard chemotherapy regimen and upfront HDCT demonstrated improved outcomes. Our data suggest a minimum of two HDCT cycles with ASCT should be standard of care for patients with RR GCC. Failure of HDCT results in a poor prognosis with only 10% of patients achieving lasting remission with salvage therapy.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1

Similar content being viewed by others

References

  1. Nigam M, Aschebrook-Kilfoy B, Shikanov S, Eggener S. Increasing incidence of testicular cancer in the United States and Europe between 1992 and 2009. World J Urol. 2015;33:623–31. https://doi.org/10.1007/s00345-014-1361-y.

    Article  PubMed  Google Scholar 

  2. Popovic L, Matovina-Brko G, Popovic M, Petrovic D, Cvetanovic A, Vukojevic J, et al. High dose chemotherapy with stem cell support in the treatment of testicular cancer. World J Stem Cells. 2015;7:1222–32. https://doi.org/10.4252/wjsc.v7.i11.1222.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Hanna NH, Einhorn LH. Testicular cancer--discoveries and updates. N Engl J Med. 2014;371:2005–16. https://doi.org/10.1056/NEJMra1407550.

    Article  CAS  PubMed  Google Scholar 

  4. Ko JJ, Bernard B, Tran B, Li H, Asif T, Stukalin I, et al. Conditional survival of patients with metastatic testicular germ cell tumors treated with first-line curative therapy. J Clin Oncol. 2016;34:714–20.

    Article  CAS  Google Scholar 

  5. De Giorgi U, Rosti G, Papiani G, Marangolo M. The status of high-dose chemotherapy with hematopoietic stem cell transplantation in germ cell tumor patients. Haematologica. 2002;87:95–104.

    PubMed  Google Scholar 

  6. Pico JL, Rosti G, Kramar A, Wandt H, Koza V, Salvioni R, et al. A randomised trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumours. Ann Oncol. 2005;16:1152–9. https://doi.org/10.1093/annonc/mdi228.

    Article  PubMed  Google Scholar 

  7. Oing C, Seidel C, von Amsberg G, Oechsle K, Bokemeyer C. Pharmacotherapeutic treatment of germ cell tumors: standard of care and recent developments. Expert Opin Pharmacother. 2016;17:545–60.

    Article  CAS  Google Scholar 

  8. Hanna NH, Einhorn LH. Testicular cancer—discoveries and updates. N Engl J Med. 2014;371:2005–16.

    Article  Google Scholar 

  9. Wilkinson PM, Read G. International germ cell consensus classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J Clin Oncol. 1997;15:594–603.

    Article  Google Scholar 

  10. Nichols CR, Tricot G, Williams SD, van Besien K, Loehrer PJ, Roth BJ, et al. Dose-intensive chemotherapy in refractory germ cell cancer--a phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation. J Clin Oncol. 1989;7:932–9.

    Article  CAS  Google Scholar 

  11. Ozols RF, Ihde D, Linehan WM, Jacob J, Ostchega Y, Young R. A randomized trial of standard chemotherapy va high-dose chemotherapy regimen in the treatment of poor prognosis nonseminomatous germ-cell tumors. J Clin Oncol. 1988;6:1031–40.

    Article  CAS  Google Scholar 

  12. Motzer RJ, Mazumdar M, Bajorin DF, Bosl GJ, Lyn P, Vlamis V. High-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors. J Clin Oncol. 1997;15:2546–52.

    Article  CAS  Google Scholar 

  13. Motzer RJ, Nichols CJ, Margolin KA, Bacik J, Richardson PG, Vogelzang NJ, et al. Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors. J Clin Oncol. 2007;25:247–56. https://doi.org/10.1200/jco.2005.05.4528.

    Article  CAS  PubMed  Google Scholar 

  14. Lorch A, Kollmannsberger C, Hartmann JT, Metzner B, Schmidt-Wolf IG, Berdel WE, et al. Single versus sequential high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: a prospective randomized multicenter trial of the German Testicular Cancer Study Group. J Clin Oncol. 2007;25:2778–84. https://doi.org/10.1200/jco.2006.09.2148.

    Article  CAS  PubMed  Google Scholar 

  15. Adra N, Abonour R, Althouse SK, Albany C, Hanna NH, Einhorn LH. High-dose chemotherapy and autologous peripheral-blood stem-cell transplantation for relapsed metastatic germ cell tumors: the Indiana University Experience. J Clin Oncol. 2016;35:1096–102.

    Article  Google Scholar 

  16. Ongoing Clinical Trials in Testicular Cancer. The TIGER Trial. Oncol Res Treat. 2016;39:553–6.

    Article  Google Scholar 

  17. Motzer RJ, Nichols CJ, Margolin KA, Bacik J, Richardson PG, Vogelzang NJ, et al. Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors. J Clin Oncol. 2007;25:247–56. https://doi.org/10.1200/jco.2005.05.4528.

    Article  CAS  PubMed  Google Scholar 

  18. Daugaard G, Skoneczna I, Aass N, De Wit R, De Santis M, Dumez H, et al. A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, and ifosfamide (VIP) plus stem-cell support in males with poor-prognosis germ-cell cancer. An intergroup study of EORTC, GTCSG, and Grupo Germinal (EORTC 30974). Ann Oncol. 2011;22:1054–61. https://doi.org/10.1093/annonc/mdq575.

    Article  CAS  PubMed  Google Scholar 

  19. Necchi A, Mariani L, Di Nicola M, Lo Vullo S, Nicolai N, Giannatempo P, et al. High-dose sequential chemotherapy (HDS) versus PEB chemotherapy as first-line treatment of patients with poor prognosis germ-cell tumors: mature results of an Italian randomized phase II study. Ann Oncol. 2015;26:167–72.

    Article  CAS  Google Scholar 

  20. Bokemeyer C, Kollmannsberger C, Meisner C, Harstrick A, Beyer J, Metzner B, et al. First-line high-dose chemotherapy compared with standard-dose PEB/VIP chemotherapy in patients with advanced germ cell tumors: a multivariate and matched-pair analysis. J Clin Oncol. 1999;17:3450–6.

    Article  CAS  Google Scholar 

  21. Droz JP, Kramar A, Biron P, Pico JL, Kerbrat P, Peny J, et al. Failure of high-dose cyclophosphamide and etoposide combined with double-dose cisplatin and bone marrow support in patients with high-volume metastatic nonseminomatous germ-cell tumours: mature results of a randomised trial. Eur Urol. 2007;51:739–46. https://doi.org/10.1016/j.eururo.2006.10.035.

    Article  CAS  PubMed  Google Scholar 

  22. Hartmann JT, Gauler T, Metzner B, Gerl A, Casper J, Rick O, et al. Phase I/II study of sequential dose-intensified ifosfamide, cisplatin, and etoposide plus paclitaxel as induction chemotherapy for poor prognosis germ cell tumors by the German Testicular Cancer Study Group. J Clin Oncol. 2007;25:5742–7. https://doi.org/10.1200/jco.2007.11.9099.

    Article  CAS  PubMed  Google Scholar 

  23. Banna GL, De Giorgi U, Ferrari B, Castagna L, Alloisio M, Marangolo M, et al. Is high-dose chemotherapy after primary chemotherapy a therapeutic option for patients with primary mediastinal nonseminomatous germ cell tumor? Biol Blood Marrow Transplant. 2006;12:1085–91.

    Article  CAS  Google Scholar 

  24. Schmoll HJ, Kollmannsberger C, Metzner B, Hartmann JT, Schleucher N, Schoffski P, et al. Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group. J Clin Oncol. 2003;21:4083–91. https://doi.org/10.1200/jco.2003.09.035.

    Article  CAS  PubMed  Google Scholar 

  25. Rosti G, De Giorgi U, Salvioni R, Papiani G, Sebastiani L, Argnani M, et al. Salvage high‐dose chemotherapy in patients with germ cell tumors. Cancer. 2002;95:309–15.

    Article  CAS  Google Scholar 

  26. Kollmannsberger C, Nichols C, Bamberg M, Hartmann JT, Schleucher N, Beyer J, et al. First-line high-dose chemotherapy+/- radiation therapy in patients with metastatic germ-cell cancer and brain metastases. Ann Oncol. 2000;11:553–9.

    Article  CAS  Google Scholar 

  27. Barnett MJ, Coppin CM, Murray N, Nevill TJ, Reece DE, Klingemann HG, et al. High-dose chemotherapy and autologous bone marrow transplantation for patients with poor prognosis nonseminomatous germ cell tumours. Br J Cancer. 1993;68:594–8.

    Article  CAS  Google Scholar 

  28. Droz JP, Pico JL, Ghosn M, Kramar A, Rey A, Ostronoff M, et al. A phase II trial of early intensive chemotherapy with autologous bone marrow transplantation in the treatment of poor prognosis non seminomatous germ cell tumors. Bull Cancer. 1992;79:497–507.

    CAS  PubMed  Google Scholar 

  29. Fizazi K, Pagliaro L, Laplanche A, Flechon A, Mardiak J, Geoffrois L, et al. Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial. Lancet Oncol. 2014;15:1442–50. https://doi.org/10.1016/s1470-2045(14)70490-5.

    Article  CAS  PubMed  Google Scholar 

  30. Di Nicola M, Necchi A, Nicolai N, Bengala C, Siena S, Novarino A, et al. 7100 High-dose sequential chemotherapy versus conventional-dose chemotherapy as first-line treatment for advanced poor prognosis germ-cell tumors: a multicenter Phase III Italian trial. Eur J Cancer Suppl. 2009;7:422.

    Article  Google Scholar 

  31. Chevreau C, Droz JP, Pico JL, Biron P, Kerbrat P, Cure H, et al. Early intensified chemotherapy with autologous bone marrow transplantation in first line treatment of poor risk non-seminomatous germ cell tumours. Preliminary results of a French randomized trial. Eur Urol. 1993;23:213–7.

    Article  CAS  Google Scholar 

  32. Motzer RJ, Mazumdar M, Gulati SC, Bajorin DF, Lyn P, Vlamis V, et al. Phase II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors. J Natl Cancer Inst. 1993;85:1828–35.

    Article  CAS  Google Scholar 

  33. Mulder PO, de Vries EG, Koops HS, Splinter T, Maas A, van der Geest S, et al. Chemotherapy with maximally tolerable doses of VP 16-213 and cyclophosphamide followed by autologous bone marrow transplantation for the treatment of relapsed or refractory germ cell tumors. Eur J Cancer Clin Oncol. 1988;24:675–9.

    Article  CAS  Google Scholar 

  34. Droz JP, Pico JL, Ghosn M, Gouyette A, Baume D, Piot G, et al. Long-term survivors after salvage high dose chemotherapy with bone marrow rescue in refractory germ cell cancer. Eur J Cancer (Oxford, England: 1990). 1991;27:831–5.

    Article  CAS  Google Scholar 

  35. Broun ER, Nichols CR, Kneebone P, Williams SD, Loehrer PJ, Einhorn LH, et al. Long-term outcome of patients with relapsed and refractory germ cell tumors treated with high-dose chemotherapy and autologous bone marrow rescue. Ann Intern Med. 1992;117:124–8.

    Article  CAS  Google Scholar 

  36. Nichols CR, Andersen J, Lazarus HM, Fisher H, Greer J, Stadtmauer EA, et al. High-dose carboplatin and etoposide with autologous bone marrow transplantation in refractory germ cell cancer: an Eastern Cooperative Oncology Group protocol. J Clin Oncol. 1992;10:558–63.

    Article  CAS  Google Scholar 

  37. Siegert W, Beyer J, Strohscheer I, Baurmann H, Oettle H, Zingsem J, et al. High-dose treatment with carboplatin, etoposide, and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: a phase I/II study. The German Testicular Cancer Cooperative Study Group. J Clin Oncol. 1994;12:1223–31.

    Article  CAS  Google Scholar 

  38. Beyer J, Kingreen D, Krause M, Schleicher J, Schwaner I, Schwella N, et al. Long-term survival of patients with recurrent or refractory germ cell tumors after high dose chemotherapy. Cancer. 1997;79:161–8.

    Article  CAS  Google Scholar 

  39. Flechon A, Biron P, Droz JP. High-dose chemotherapy with hematopoietic stem-cell support in germ-cell tumor patient treatment: the French experience. Int J Cancer. 1999;83:844–7.

    Article  CAS  Google Scholar 

  40. Rick O, Bokemeyer C, Beyer J, Hartmann JT, Schwella N, Kingreen D, et al. Salvage treatment with paclitaxel, ifosfamide, and cisplatin plus high-dose carboplatin, etoposide, and thiotepa followed by autologous stem-cell rescue in patients with relapsed or refractory germ cell cancer. J Clin Oncol. 2001;19:81–88.

    Article  CAS  Google Scholar 

  41. McNeish IA, Kanfer EJ, Haynes R, Giles C, Harland SJ, Driver D, et al. Paclitaxel-containing high-dose chemotherapy for relapsed or refractory testicular germ cell tumours. Br J Cancer. 2004;90:1169–75. https://doi.org/10.1038/sj.bjc.6601664.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Broun ER, Nichols CR, Gize G, Cornetta K, Hromas RA, Schacht B, et al. Tandem high dose chemotherapy with autologous bone marrow transplantation for initial relapse of testicular germ cell cancer. Cancer. 1997;79:1605–10.

    Article  CAS  Google Scholar 

  43. Rodenhuis S, de Wit R, de Mulder PH, Keizer HJ, Sleijfer DT, Lalisang RI, et al. A multi-center prospective phase II study of high-dose chemotherapy in germ-cell cancer patients relapsing from complete remission. Ann Oncol. 1999;10:1467–73.

    Article  CAS  Google Scholar 

  44. Margolin KA, Doroshow JH, Frankel P, Chow W, Leong LA, Lim D, et al. Paclitaxel-based high-dose chemotherapy with autologous stem cell rescue for relapsed germ cell cancer. Biol Blood Marrow Transplant: J Am Soc Blood Marrow Transplant. 2005;11:903–11. https://doi.org/10.1016/j.bbmt.2005.07.010.

    Article  CAS  Google Scholar 

  45. Lotz JP, Bui B, Gomez F, Theodore C, Caty A, Fizazi K. et al. Sequential high-dose chemotherapy protocol for relapsed poor prognosis germ cell tumors combining two mobilization and cytoreductive treatments followed by three high-dose chemotherapy regimens supported by autologous stem cell transplantation. Results of the phase II multicentric TAXIF trial.Ann Oncol. 2005; 16:411–8. https://doi.org/10.1093/annonc/mdi087.

    Article  PubMed  Google Scholar 

  46. Motzer RJ, Sheinfeld J, Mazumdar M, Bains M, Mariani T, Bacik J, et al. Paclitaxel, ifosfamide, and cisplatin second-line therapy for patients with relapsed testicular germ cell cancer. J Clin Oncol. 2000;18:2413–8.

    Article  CAS  Google Scholar 

  47. Kondagunta GV, Bacik J, Sheinfeld J, Bajorin D, Bains M, Reich L, et al. Paclitaxel plus Ifosfamide followed by high-dose carboplatin plus etoposide in previously treated germ cell tumors. J Clin Oncol. 2007;25:85–90. https://doi.org/10.1200/jco.2006.06.9401.

    Article  CAS  PubMed  Google Scholar 

  48. Nieto Y, Tu SM, Bassett R, Jones RB, Gulbis AM, Tannir N, et al. Bevacizumab/high-dose chemotherapy with autologous stem-cell transplant for poor-risk relapsed or refractory germ-cell tumors. Ann Oncol. 2015;26:2125–32. https://doi.org/10.1093/annonc/mdv310

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Selle F, Wittnebel S, Biron P, Gravis G, Roubaud G, Bui BN, et al. A phase II trial of high-dose chemotherapy (HDCT) supported by hematopoietic stem-cell transplantation (HSCT) in germ-cell tumors (GCTS) patients failing cisplatin-based chemotherapy: the multicentric taxif ii study. Ann Oncol. 2014;25:1775–82.

    Article  CAS  Google Scholar 

  50. Feldman DR, Sheinfeld J, Bajorin DF, Fischer P, Turkula S, Ishill N, et al. TI-CE high-dose chemotherapy for patients with previously treated germ cell tumors: results and prognostic factor analysis. J Clin Oncol. 2010;28:1706–13. https://doi.org/10.1200/jco.2009.25.1561.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Kondagunta GV, Bacik J, Donadio A, Bajorin D, Marion S, Sheinfeld J, et al. Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors. J Clin Oncol. 2005;23:6549–55. https://doi.org/10.1200/jco.2005.19.638

    Article  CAS  PubMed  Google Scholar 

  52. Einhorn LH, Brames MJ, Juliar B, Williams SD. Phase II study of paclitaxel plus gemcitabine salvage chemotherapy for germ cell tumors after progression following high-dose chemotherapy with tandem transplant. J Clin Oncol. 2007;25:513–6.

    Article  CAS  Google Scholar 

  53. Einhorn LH, Williams SD, Chamness A, Brames MJ, Perkins SM, Abonour R. High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. N Engl J Med. 2007;357:340–8. https://doi.org/10.1056/NEJMoa067749

    Article  CAS  PubMed  Google Scholar 

  54. Vaena DA, Abonour R, Einhorn LH. Long-term survival after high-dose salvage chemotherapy for germ cell malignancies with adverse prognostic variables. J Clin Oncol. 2003;21:4100–4.

    Article  CAS  Google Scholar 

  55. Bhatia S, Abonour R, Porcu P, Seshadri R, Nichols C, Cornetta K, et al. High-dose chemotherapy as initial salvage chemotherapy in patients with relapsed testicular cancer. J Clin Oncol. 2000;18:3346–51.

    Article  CAS  Google Scholar 

  56. Berger LA, Bokemeyer C, Lorch A, Hentrich M, Kopp HG, Gauler TC, et al. First salvage treatment in patients with advanced germ cell cancer after cisplatin-based chemotherapy: analysis of a registry of the German Testicular Cancer Study Group (GTCSG). J Cancer Res Clin Oncol. 2014;140:1211–20. https://doi.org/10.1007/s00432-014-1661-z

    Article  CAS  PubMed  Google Scholar 

  57. Beyer J, Stenning S, Gerl A, Fossa S, Siegert W. High-dose versus conventional-dose chemotherapy as first-salvage treatment in patients with non-seminomatous germ-cell tumors: a matched-pair analysis. Ann Oncol. 2002;13:599–605.

    Article  CAS  Google Scholar 

  58. Lorch A, Bascoul-Mollevi C, Kramar A, Einhorn L, Necchi A, Massard C, et al. Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: evidence from a large international database. J Clin Oncol. 2011;29:2178–84.

    Article  Google Scholar 

  59. Agarwal R, Dvorak CC, Stockerl-Goldstein KE, Johnston L, Srinivas S. High-dose chemotherapy followed by stem cell rescue for high-risk germ cell tumors: the Stanford experience. Bone Marrow Transplant. 2009;43:547–52.

    Article  CAS  Google Scholar 

  60. Ibrahim A, Zambon E, Bourhis JH, Ostronoff M, Beaujean F, Viens P, et al. High-dose chemotherapy with etoposide, cyclophosphamide and escalating dose of carboplatin followed by autologous bone marrow transplantation in cancer patients. A pilot study. Eur J Cancer. 1993;29:1398–403.

    Article  Google Scholar 

  61. Pico JL, Rosti G, Kramar A, Wandt H, Koza V, Salvioni R, et al. A randomised trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumours. Ann Oncol. 2005;16:1152–9.

    Article  Google Scholar 

  62. Motzer RJ, Mazumdar M, Sheinfeld J, Bajorin DF, Macapinlac HA, Bains M, et al. Sequential dose-intensive paclitaxel, ifosfamide, carboplatin, and etoposide salvage therapy for germ cell tumor patients. J Clin Oncol. 2000;18:1173–80.

    Article  CAS  Google Scholar 

  63. Lorch A. A practice-changing step forward in germ-cell cancer? Lancet Oncol. 2014;15:1409–10.

    Article  Google Scholar 

  64. Thomas F, Moeung S, Broutin S, Guitton J, Boisdron-Celle M, Ciccolini J, et al. Individualization of high dose carboplatin based on therapeutic drug monitoring (TDM) for the treatment of testicular germ cell tumors (TICE protocol): results of a multicenter phase II study. Am Soc Clin Oncol. 2017;35:4554–4554.

    Article  Google Scholar 

  65. Kalra M, Adra N, Mckay J, Abonour R, Hanna NH, Einhorn LH. High-dose chemotherapy (HDCT) plus peripheral-blood stem-cell transplant (PBSCT) for patients (pts) with relapsed germ-cell tumors (GCT) and active brain metastases (mets). Am Soc Clin Oncol. 2017;35:4558–4558.

    Article  Google Scholar 

  66. Berger GK, Gee K, Votruba C, McBride A, Anwer F. Potential application and prevalence of the CD30 (Ki-1) antigen among solid tumors: a focus review of the literature. Crit Rev Oncol/Hematol. 2017;113:8–17.

    Article  Google Scholar 

  67. Sikaria S, Chopra S, Xiong S, Yang D, Theuer CP, Hu J. Endoglin (CD105) expression in non-seminomatous germ cell tumors. Am Soc Clin Oncol. 2017;35:e16036.

    Article  Google Scholar 

  68. Rosen L, Gordon M, Hurwitz H, Wong M, Adams B, Alvarez D, et al. Early evidence of tolerability and clinical activity from a phase I study of TRC105 (anti-CD105 antibody) in patients with advanced refractory cancer. J Clin Oncol. 2009;27:3518.

    Article  Google Scholar 

  69. Adra N, Althouse SK, Ammakkanavar NR, Radovich M, Albany C, Vaughn DJ, et al. Phase II trial of pembrolizumab in patients (pts) with incurable platinum refractory germ cell tumors (GCT). Am Soc Clin Oncol. 2017;35:4520–4520.

    Article  Google Scholar 

  70. Chovanec M, Cierna Z, Miskovska V, Machalekova K, Kalavska K, Rejlekova K, et al. Systemic immune-inflammation index is prognostic in testicular germ cell tumors with PD-L1 expressing tumor infiltrating lymphocytes. Am Soc Clin Oncol. 2017;35:e16042.

    Article  Google Scholar 

Download references

Acknowledgements

This work was supported in part by grant P30 CA023074 from the National Cancer Institute, National Institutes of Health, Bethesda, MD.

Author information

Authors and Affiliations

  1. Department of Hematology and Oncology, Mayo Clinic, Rochester, MN, 55905, USA

    Irbaz bin Riaz

  2. Department of Medicine, Bronx Lebanon Hospital, Mount Sinai School of Medicine, Bronx, NY, 104576, USA

    Muhammad Umar

  3. Department of Biostatics, Mel and Enid Zuckerman College of Public Health, University of Arizona, Tucson, AZ, 85721, USA

    Umar Zahid

  4. Division of Hematology Oncology, Department of Medicine, University of Miami, Miami, FL, 33146, USA

    Muhammad Husnain

  5. Division of Hematology Oncology, Department of Medicine, University of Arizona, Tucson, AZ, 85724, USA

    Ahmad Iftikhar, Farva Razia Gondal, Frederick Ahman & Faiz Anwer

  6. College of Pharmacy, University of Arizona, Tucson, AZ, 85721, USA

    Ali McBride

  7. Department of Medicine, University of Arizona, Tucson, AZ, 85721, USA

    Jawad Bilal, Zeeshan Ali & Qurat Ul Ain Riaz Sipra

  8. Medical College, Aga Khan University, Sindh, Karachi, 74800, Pakistan

    Asad Javed & Sara Akbar

  9. Department of Hematology Oncology, Mayo Clinic, Scottsdale, AZ, 85259, USA

    Parminder Singh

Authors
  1. Irbaz bin Riaz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Muhammad Umar
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Umar Zahid
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Muhammad Husnain
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ahmad Iftikhar
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ali McBride
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jawad Bilal
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Asad Javed
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Sara Akbar
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Parminder Singh
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Zeeshan Ali
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Qurat Ul Ain Riaz Sipra
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Farva Razia Gondal
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Frederick Ahman
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Faiz Anwer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Faiz Anwer.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

bin Riaz, I., Umar, M., Zahid, U. et al. Role of one, two and three doses of high-dose chemotherapy with autologous transplantation in the treatment of high-risk or relapsed testicular cancer: a systematic review. Bone Marrow Transplant 53, 1242–1254 (2018). https://doi.org/10.1038/s41409-018-0188-3

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41409-018-0188-3

Search

Advanced search

Quick links